NASDAQ:ABOS Acumen Pharmaceuticals (ABOS) Stock Price, News & Analysis $2.22 -0.05 (-2.20%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$2.15▼$2.2750-Day Range$2.22▼$3.5452-Week Range$1.81▼$5.86Volume324,831 shsAverage Volume366,143 shsMarket Capitalization$133.38 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Acumen Pharmaceuticals alerts: Email Address Acumen Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.25 Rating ScoreUpside/Downside305.4% Upside$9.00 Price TargetShort InterestHealthy4.11% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.32) to ($1.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.61 out of 5 starsMedical Sector630th out of 910 stocksBiological Products, Except Diagnostic Industry102nd out of 155 stocks 3.6 Analyst's Opinion Consensus RatingAcumen Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAcumen Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Acumen Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.11% of the float of Acumen Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAcumen Pharmaceuticals has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Acumen Pharmaceuticals has recently decreased by 1.07%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAcumen Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcumen Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABOS. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Acumen Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 9 people have searched for ABOS on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Acumen Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acumen Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.10% of the stock of Acumen Pharmaceuticals is held by insiders.Percentage Held by Institutions71.01% of the stock of Acumen Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Acumen Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Acumen Pharmaceuticals are expected to decrease in the coming year, from ($1.32) to ($1.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acumen Pharmaceuticals is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acumen Pharmaceuticals is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcumen Pharmaceuticals has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Acumen Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThis P/L chart will make your eyes pop Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Acumen Pharmaceuticals Stock (NASDAQ:ABOS)Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Read More ABOS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABOS Stock News HeadlinesSeptember 3, 2024 | globenewswire.comAcumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor ConferenceAugust 14, 2024 | markets.businessinsider.comBuy Rating for Acumen Pharmaceuticals Backed by Promising Alzheimer’s Treatment Advances and Strong FinancialsSeptember 7, 2024 | Sasco Gold LLC (Ad)Say Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... August 14, 2024 | msn.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | finance.yahoo.comQ2 2024 Acumen Pharmaceuticals Inc Earnings CallAugust 13, 2024 | seekingalpha.comAcumen Pharmaceuticals, Inc. (ABOS) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | markets.businessinsider.comAcumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business HighlightsAugust 6, 2024 | globenewswire.comAcumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024September 7, 2024 | Sasco Gold LLC (Ad)Say Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... July 30, 2024 | seekingalpha.comAcumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer'sJuly 29, 2024 | markets.businessinsider.comAcumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s DiseaseJuly 29, 2024 | globenewswire.comAcumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer's DiseaseJuly 28, 2024 | globenewswire.comAcumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC®) 2024July 26, 2024 | msn.comCitigroup Initiates Coverage of Acumen Pharmaceuticals (ABOS) with Buy RecommendationMay 16, 2024 | markets.businessinsider.comBuy Rating Justified: Acumen Pharmaceuticals’ Promising Position in Alzheimer’s Treatment MarketMay 16, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Acumen Pharmaceuticals (ABOS) and DENTSPLY SIRONA (XRAY)May 15, 2024 | finance.yahoo.comQ1 2024 Acumen Pharmaceuticals Inc Earnings CallMay 15, 2024 | finance.yahoo.comAcumen Pharmaceuticals Inc (ABOS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...See More Headlines Receive ABOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acumen Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABOS CUSIPN/A CIK1576885 Webwww.acumenpharm.com Phone434-297-1000FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$15.00 Low Stock Price Target$6.00 Potential Upside/Downside+305.4%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-24.63% Return on Assets-21.87% Debt Debt-to-Equity Ratio0.12 Current Ratio17.37 Quick Ratio17.37 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.06 per share Price / Book0.55Miscellaneous Outstanding Shares60,080,000Free Float55,814,000Market Cap$133.38 million OptionableOptionable Beta0.09 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Daniel J. O'Connell M.B.A. (Age 53)CEO & Director Comp: $901.2kMr. Matt ZugaCFO & Chief Business OfficerMr. Derek M. Meisner Esq. (Age 53)J.D., Chief Legal Officer & Corporate Secretary Comp: $240.17kDr. James Doherty Ph.D. (Age 56)President & Chief Development Officer Dr. Grant A. Krafft Ph.D.Co-FounderDr. Caleb E. Finch Ph.D.Co-FounderDr. William L. Klein Ph.D.Co-FounderMr. Russell Barton M.S. (Age 65)Chief Operating Officer Comp: $223.68kMs. Kelly CarranzaVice President, Finance & Accounting and Corporate ControllerMs. Alex Braun M.B.A.VP & Head of Investor RelationsMore ExecutivesKey CompetitorsParatek PharmaceuticalsNASDAQ:PRTKAthira PharmaNASDAQ:ATHAOvid TherapeuticsNASDAQ:OVIDChiasmaNASDAQ:CHMAEpizymeNASDAQ:EPZMView All CompetitorsInsiders & InstitutionsMurchinson Ltd.Bought 56,250 shares on 8/16/2024Ownership: 0.094%Millennium Management LLCSold 675,456 shares on 8/15/2024Ownership: 3.252%Murchinson Ltd.Bought 56,250 shares on 8/14/2024Ownership: 0.094%Marathon Trading Investment Management LLCSold 33,702 shares on 8/12/2024Ownership: 0.044%Dimensional Fund Advisors LPSold 5,180 shares on 8/9/2024Ownership: 0.094%View All Insider TransactionsView All Institutional Transactions ABOS Stock Analysis - Frequently Asked Questions How have ABOS shares performed this year? Acumen Pharmaceuticals' stock was trading at $3.84 at the beginning of 2024. Since then, ABOS stock has decreased by 42.2% and is now trading at $2.22. View the best growth stocks for 2024 here. How were Acumen Pharmaceuticals' earnings last quarter? Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) announced its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.06. When did Acumen Pharmaceuticals IPO? Acumen Pharmaceuticals (ABOS) raised $125 million in an IPO on Thursday, July 1st 2021. The company issued 8,333,333 shares at $14.00-$16.00 per share. Who are Acumen Pharmaceuticals' major shareholders? Acumen Pharmaceuticals' top institutional investors include Millennium Management LLC (3.25%), Renaissance Technologies LLC (0.56%), Bank of New York Mellon Corp (0.21%) and Dimensional Fund Advisors LP (0.09%). Insiders that own company stock include Ra Capital Management, LP, Daniel Joseph Oconnell, Matt Zuga, Derek M Meisner, Russell Barton and Jeffrey L Ives. View institutional ownership trends. How do I buy shares of Acumen Pharmaceuticals? Shares of ABOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ABOS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
